Skip to main content

Drug Interactions between Izba and latanoprost / timolol ophthalmic

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

latanoprost ophthalmic travoprost ophthalmic

Applies to: latanoprost / timolol ophthalmic and Izba (travoprost ophthalmic)

GENERALLY AVOID: Concurrent use of multiple prostaglandin analogs, or a selective prostaglandin EP2 receptor agonist and a prostaglandin analog, as well as more frequent administration of a prostaglandin analog than recommended, may reduce the intraocular pressure (IOP) lowering effects of these agents. A case series of 3 patients described IOP elevations of 6 to 23 mmHg two to five weeks after bimatoprost was added to a latanoprost regimen. The precise mechanism of interaction has not been established, although the combination exceeded the dose-response curve, which may have led to the paradoxical effects on IOP. Other factors such as disease state and patient compliance may also have contributed. In a randomized clinical trial of 18 patients with non-advanced primary open angle glaucoma, mean IOP increased by 1.8 mmHg four weeks after the addition of bimatoprost to preexisting latanoprost treatment, but returned to baseline after discontinuation of bimatoprost.

MANAGEMENT: Concomitant administration of two or more prostaglandin analogs, or a selective prostaglandin EP2 receptor agonist and a prostaglandin analog, or more frequent administration of a prostaglandin analog than approved by the manufacturers, is generally not recommended.

References

  1. (2001) "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn
  2. Herndon LW, Asrani SG, Williams GH, Challa P, Lee PP (2002) "Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost." Arch Ophthalmol, 120, p. 847-9
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  4. Cerner Multum, Inc. "Australian Product Information."
  5. EMA. European Medicines Agency. European Union (2013) EMA - List of medicines under additional monitoring. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852
  6. Doi LM, Melo LA, Prata JA (2005) "Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomized clinical trial." Br J Ophthalmol, 89, p. 547-9
  7. Matsuo M, Matsuoka Y, Tanito M (2022) "Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension" Clin Ophthalmol, 16, p. 1261-79
View all 7 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Prostaglandin agonist ophthalmics

Therapeutic duplication

The recommended maximum number of medicines in the 'prostaglandin agonist ophthalmics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'prostaglandin agonist ophthalmics' category:

  • Izba (travoprost ophthalmic)
  • latanoprost/timolol ophthalmic

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer